The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
Bisphosphonates are effective in the management of bone disease in patients with multiple myeloma and recent reports have suggested that they may also have an anti-tumour activity. In support of this, we have previously demonstrated that bisphosphonates can induce myeloma cell apoptosis in vitro; ho...
Auteurs principaux: | Shipman, C, Vanderkerken, K, Rogers, M, Lippitt, J, Asosingh, K, Hughes, D, Van Camp, B, Russell, R, Croucher, P |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2000
|
Documents similaires
-
Bisphosphonates--mechanisms of action in multiple myeloma.
par: Shipman, C, et autres
Publié: (2000) -
Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
par: Croucher, P, et autres
Publié: (2003) -
Bisphosphonates and in vivo models of multiple myeloma - Reply
par: Shipman, C, et autres
Publié: (2001) -
Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
par: Vanderkerken, K, et autres
Publié: (2003) -
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
par: Croucher, P, et autres
Publié: (2001)